Skip to main content

Table 4 Relationship between MVD, MVA, LVD or LVA and clinicopathological variables in peritumoral area of Xp11.2 translocation RCC

From: Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?

Variable

No.

Peri-tumor (Mean ± SD)

MVD

P-value

MVA

P-value

LVD

P-value

LVA

P-value

Pathological T stage

  

0.399

 

0.563

 

0.004

 

< 0.001

 pT1/pT2

29

107 ± 10

 

34,718 ± 6183

 

9 ± 3

 

2914 ± 1125

 

 pT3/pT4

5

111 ± 8

 

36,468 ± 6259

 

13 ± 3

 

5719 ± 1746

 

Pathological N stage

  

0.397

 

0.569

 

0.001

 

0.011

 pN0

27

106 ± 10

 

34,201 ± 6083

 

9 ± 3

 

2837 ± 1089

 

 pN1

7

114 ± 8

 

37,960 ± 5767

 

13 ± 3

 

5212 ± 1778

 

Clinical M stage

  

0.419

 

0.175

 

0.009

 

0.002

 cM0

32

108 ± 10

 

34,713 ± 6223

 

9 ± 3

 

3125 ± 1381

 

 cM1

2

114 ± 4

 

39,169 ± 1592

 

13 ± 2

 

6539 ± 356

 

AJCC stage

  

0.059

 

0.151

 

0.001

 

0.011

 I/II

27

106 ± 10

 

34,201 ± 6083

 

9 ± 3

 

2837 ± 1089

 

 III/IV

7

114 ± 8

 

37,960 ± 5767

 

13 ± 3

 

5212 ± 1778

 

WHO/ISUP grade

  

0.103

 

0.181

 

0.007

 

0.002

 1/2

24

106 ± 10

 

34,059 ± 6357

 

9 ± 3

 

2822 ± 1146

 

 3/4

10

112 ± 9

 

37,174 ± 5189

 

12 ± 3

 

4536 ± 1833

 
  1. MVD Microvascular density, MVA Microvascular area, LVA Lymph vessel area, LVD Lymph vessel density, AJCC American Joint Committee On Cancer, WHO/ISUP World Health Organization/International Society of Urological Pathology, Xp11.2 translocation RCC Xp11.2 translocation renal cell carcinoma
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us